WHO ICTRP trial
The effect of Nintedanib in post-COVID-19 lung fibrosis: an observational study
TCTR20220426001 · Thai Clinical Trials Registry (TCTR) · Not Recruiting
Key facts
| Trial ID | TCTR20220426001 |
|---|---|
| Public title | The effect of Nintedanib in post-COVID-19 lung fibrosis: an observational study |
| Scientific title | The effect of Nintedanib in post-COVID-19 lung fibrosis: an observational study |
| Primary sponsor | Faculty of Medicine, Thammasat University |
| Registry | Thai Clinical Trials Registry (TCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational |
| Countries | Thailand |
| Conditions | Patients with COVID-19 pneumonia and lung fibrosis COVID-19 Pneumonia Lung fibrosis Nintedanib Antifibrotic Oxygenation Chest radiograph Mortality;COVID-19 Pneumonia Lung fibrosis Nintedanib Antifibrotic Oxygenation Chest radiograph… |
| Interventions | Patients with COVID-19 pneumonia and lung fibrosis treated with nintedanib at least 5 days,Patients with COVID-19 pneumonia and lung fibrosis treated with standand medications (no nintedanib);Treatment,Treatment;Nintedanib group,Control… |
| Registration date | Apr 26, 2022 |
| Target size | 29 |
| Secondary IDs | Nil Known |
| Registry page | thaiclinicaltrials.org |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: